Story · Medicine & Biotech

Beyond MSI Status: A New Biomarker of Immunotherapy Resistance in Colorectal Cancer

1 outlet · first reported by OncoDaily on

Immune checkpoint inhibitors have transformed the treatment of mismatch repair-deficient/microsatellite instability-high (dMMR/MSI) colorectal cancer, producing durable responses in many patients. However, not all patients with dMMR/MSI tumors benefit from immunotherapy, (OncoDaily)

Coverage, in order

  1. OncoDaily obscure
    Beyond MSI Status: A New Biomarker of Immunotherapy Resistance in Colorectal Cancer

    Immune checkpoint inhibitors have transformed the treatment of mismatch repair-deficient/microsatellite instability-high (dMMR/MSI) colorectal cancer, producing durable responses in many patients. However, not all patients with dMMR/MSI tumors benefit from immunotherapy,

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.